International Journal of Molecular Sciences
October 13, 2022
Stephen M Stahl, Sara de Martin, Andrea Mattarei et al.
This article presents a mechanism of action hypothesis to explain the rapid antidepressant effects of esmethadone (REL-1017) and other uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists and presents a corresponding mechanism of disease hypothesis for major depressive disorder (MDD). Esmethadone and other uncompetitive NMDAR antagonists may restore physiological neural plasticity in...
BMC Psychiatry
October 3, 2022
S. Ahuja, Madeline Brendle, Leo Smart et al.
Background Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics. However, a characterization of the outpatient population receiving IM ketamine treatment and an evaluation of the real-world depression, anxiety, and safety outcomes...
Neuropharmacology
October 1, 2022
Kai Zhang, Yitan Yao, Kenji Hashimoto
68 citations
Depression is a well-known serious mental illness, and the onset of treatment using traditional antidepressants is frequently delayed by several weeks. Moreover, numerous patients with depression fail to respond to therapy. One major breakthrough in antidepressant therapy is that subanesthetic ketamine doses can rapidly alleviate depressive symptoms within hours of administering a single dose,...
Psychological Medicine
October 1, 2022
Ashish K Sahib, Joana R Loureiro, Megha M Vasavada et al.
36 citations
Subanesthetic ketamine infusion therapy can produce fast-acting antidepressant effects in patients with major depression. How single and repeated ketamine treatment modulates the whole-brain functional connectome to affect clinical outcomes remains uncharacterized. Data-driven whole brain functional connectivity (FC) analysis was used to identify the functional connections modified by ketamine...
Frontiers in Psychiatry
September 28, 2022
K. Hassan, W. Struthers, Aditya Sankarabhotla et al.
25 citations
Intravenous and intranasal ketamine have been shown to be effective therapeutic options in patients suffering from treatment-resistant depression (TRD). The use of sublingual (SL), rapid dissolve ketamine tablets (RDT) offers a novel approach for delivery for mental health indications. This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve...
JAMA Psychiatry
September 28, 2022
Hugo Bottemanne, Orphée Morlaàs, Anne Claret et al.
59 citations
Key Points Question What are the effects of ketamine on belief updating in patients with treatment-resistant depression (TRD)? Findings This case-control study in patients with TRD showed that belief updating became more optimistically biased as soon as 4 hours after a first ketamine infusion. This early cognitive effect of ketamine was formalized by stronger asymmetrical reinforcement learning...
International Journal of Molecular Sciences
September 28, 2022
Dominika Psiuk, Emilia Magdalena Nowak, Natalia Dycha et al.
36 citations
This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment—psilocybin and esketamine. The former is a naturally occurring psychedelic. The latter was invented in the laboratory exactly 60 years ago. Although the substances were controversial in the past, recent studies indicate the potential of those...
Science Signaling
September 27, 2022
Leslie K. Ferrarelli
A stress hormone enables the antidepressant action of ketamine.
Indian Journal of Behavioural Sciences
September 26, 2022
Akanksha Varshney, Shravan Kumar, Ved Prakash Gupta et al.
1 citation
In treatment-resistant unipolar and bipolar depression, there is increasing evidence to support the fast, although the short-lived antidepressant effect of ketamine, a non-competitive glutamate N-methyl-D-aspartate receptor antagonist. Ketamine has been shown to cause transient mood elevation or euphoria, dissociative symptoms and psychotomimetic effects when administered in unipolar or bipolar...
Frontiers in Psychiatry
September 21, 2022
Laurent Elkrief, Olivier Payette, Jean-Nicolas Foucault et al.
15 citations
About a third of patients suffering from major depression develop treatment-resistant depression (TRD). Although repetitive transcranial magnetic stimulation (rTMS) and intravenous ketamine have proven effective for the management of TRD, many patients remain refractory to treatment. We present the case of a patient suffering from bipolar TRD. The patient was referred to us after failure to...